UNSPSC 51113601: Irofulven

This classification denotes an antineoplastic alkylating agent with the molecular formula C15H18O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 6B799IH05A, chemically known as spiro(cyclopropane-1,5(5h)-inden)-7(6h)-one, 6-hydroxy-3-(hydroxymethyl)-2,4,6-trimethyl-, (r)- but more generally known as irofulven, which bears U.S. National Institutes of Health Compound Identifier 148189. European Medicines Agency schedules Irofulven in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02773MIG.

UNSPSC 51113601 Irofulven is a Commodity code for a specific chemotherapy agent used in cancer treatment. State and local governments procure irofulven primarily through health departments, hospital systems, and public health agencies that operate oncology clinics or cancer treatment programs. The drug is a topoisomerase I inhibitor indicated for certain solid tumors and is typically acquired as part of bulk pharmaceutical purchasing for direct patient administration in public healthcare settings.

The recent-opportunities block in the source contains no posted solicitations for irofulven under this code. Without evidence of active state or local procurement activity in the record, the code shows no current buying signals to assess geographic concentration, issuing-body patterns, or near-term opportunities.